Shenzhen, China – Beike Biotechnology has been granted AABB accreditation for cord blood processing, storage, distribution, cell therapy activity (MSC, cord blood; MSC, placenta; NC, whole blood), somatic cell processing, storage, and distribution at the Shenzhen integrated cell bank according to Dr. Jay E. Menitove, president of AABB. This confirmation follows the announcement of preparation for AABB accreditation by Beike Biotechnology from earlier this year, and is now Beike’s second AABB accredited facility.
AABB accreditation follows an intensive on-site assessment by specially trained AABB assessors and establishes that the level of technical and administrative performance within the facility meets or exceeds the standards set by AABB. By successfully meeting those requirements, Beike Biotechnology joins similar facilities located throughout the United States and around the world that also have earned AABB Accreditation. “The AABB’s Accreditation procedures are voluntary,” president of AABB explained. “Beike Biotechnology has sought AABB Accreditation because this program assists facilities around the world in achieving excellence by promoting a level of professional and technical expertise that contributes to quality performance and patient safety.“
AABB’s Accreditation Program contributes to the quality and safety of collecting, processing, testing, distributing and administering blood and cellular therapy products. The Accreditation Program assesses the quality and operational systems in place within a facility. The basis for assessment is compliance with AABB standards, Code of Federal Regulations and other federal guidance documents.
The AABB Accreditation program has been recognized by the International Society for Quality in Healthcare (ISQua). In June 1995, AABB was granted “deemed status” as an accrediting organization under the clinical Laboratory Improvement Amendments of 1998 (CLIA ‘ 88) program. This granting of “deemed status” indicates that the Canters for Medicare and Medicaid (CMS) has found the AABB accreditation process to provide reasonable assurance that the facilities accredited by it meet or exceed the conditions required by federal law and regulations.
AABB grants accreditation for:
- – Donor Centers-Collection, Processing, Testing, and Distribution
– Transfusion Services-Testing (Pretransfusion, Compatibility), Blood Administration
– Cellular Therapy (Hematopoietic Progenitor Cells, Cord Blood, Somatic Cells)
– Immunohematology Reference Laboratories
– Perioperative Services
– Relationship/Parentage Testing
– Molecular Testing for Red Cell, Platelet, and Neutrophil Antigens
Established in 1947, AABB (formerly known as the American Association of Blood Bank) is an international, not-for-profit association dedicated to the advancement of science and the practice of transfusion medicine and related biological therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs and services to optimize patient and donor care and safety.
About Beike Biotechnology Co., Ltd.
Beike Biotechnology Co., Ltd. (http://beikebiotech.com/) is the world’s largest stem cell provider and China’s leading cellular therapy company focusing on research, cell banking, and the production of adult stem cells and immunotherapies for medical use. Headquartered in Shenzhen (near Hong Kong), Beike has been committed to advancing cellular therapy since 2005.